Changes in lung function among treated HIV-positive and HIV-negative individuals: analysis of the prospective AGEhIV cohort study
Sebastiaan O Verboeket, Anders Boyd, Ferdinand W.N.M. Wit, Eveline Verheij, Maarten F. Schim van der Loeff, Neeltje A. Kootstra, Marc van der Valk, Reindert P. van Steenwijk, Michael Drummond, Gregory D. Kirk, Peter Reiss
Abstract
BACKGROUND: IV cohort accounting for smoking behaviour and other risk factors. METHODS: and FVC decline and CD4 and CD8 T-cell counts, and plasma concentrations of C-reactive protein (CRP), interleukin 6, soluble CD14, soluble CD163, and intestinal fatty-acid-binding protein in separate models. The study is registered at ClinicalTrials.gov, NCT01466582. FINDINGS: and FVC among HIV-positive participants but not among HIV-negative participants. INTERPRETATION: /FVC ratio. These changes were independent of smoking and might have been driven by ongoing interstitial or small airway damage, potentially related to increased inflammation. FUNDING: ZonMW, Aidsfonds, Gilead Sciences, ViiV Healthcare, Janssen Pharmaceuticals, Merck.